finasteride injection (IVL3001) / Inventage Lab - LARVOL DELTA

A Phase I, Open-Label, Sequential, Single-Dose Clinical Trial to Evaluate the Pharmacokinetic, Pharmacodynamic, and Safety of IVL3001, a Finasteride-Based Novel Long-Acting Injection for Androgenetic Alopecia. (PubMed, Adv Ther) - P1/2 | "The present study represents the first clinical trial to evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD), and tolerability of finasteride long-acting injectables (LAI) in adults. The rapid onset of action sustained effective drug concentration and the prolonged half-life of IVL3001 suggest that it offers multiple benefits over conventional oral formulations in terms of therapeutic response and compliance."

Journal • PK/PD data • Alopecia • Immunology

SINGLE ASCENDING DOSE STUDY OF THE NOVEL DONEPEZIL LONG-ACTING INJECTION VERSUS ARICEPT® TABLETS IN HEALTHY ADULT PARTICIPANTS (ADPD 2024) - "A major difference in the observed PK over 672hours following SC IVL3001 was the more consistent donepezil plasma concentrations without initial burst and the absence of sharp fluctuations in peak and trough levels which are typical of daily oral dosing. The safety and pharmacokinetic/pharmacodynamic properties of IVL3003 confirmed through this trial showed that it achieved a fast effective concentration and maintained a stable effective concentration, unlike the conventional oral drug administered daily. IVL3003 was confirmed to be developed as a therapeutic agent for Alzheimer's disease (AD)."

Clinical • Alzheimer's Disease • CNS Disorders • Dementia • Pain

A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001 (clinicaltrials.gov) - P1/2 | N=40 | Completed | Sponsor: Inventage Lab., Inc. | Not yet recruiting ➔ Completed

Trial completion • Alopecia

A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001 (clinicaltrials.gov) - P1/2; N=46; Not yet recruiting; Sponsor: Inventage Lab., Inc.

Clinical • New P1/2 trial • Alopecia